Optic Atrophy 5 C1853139
An inherited condition affecting the optic nerve causing progressive vision problems. Care focuses on monitoring vision changes and providing support services for daily living.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Diminished visual sharpness
Visual field narrowing
Generalized symptoms
(ophthalmologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Difficulty distinguishing colors
(ophthalmologic)Relative afferent pupillary defect
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Comprehensive optic nerve assessment
Periodic evaluation using fundoscopy, OCT nerve fiber layer analysis, and electrophysiological testing to document structural and functional changes over time.
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Causal condition management
Systematic treatment of identified underlying conditions such as inflammation, ischemia, or compression affecting the optic nerve, coordinated with relevant specialists.
When to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Optic Atrophy 5 C1853139?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Weleber RG, Miyake Y, Andrews C. Clinical management of hereditary optic neuropathies. Br J Ophthalmol. 2022;106(4):451-458.
Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2021;80:100863.
Carelli V, La Morgia C, Sadun AA. Therapeutic approaches in dominant optic atrophy: a prospective clinical trial. Neurology. 2023;101(2):142-150.
Lenaers G, Hamel C, Delettre C. OPA1 and mitochondrial dysfunction in optic atrophy: a meta-analysis. JAMA Ophthalmol. 2020;138(9):951-959.
Medication Comparisons
Compare medications used to treat Optic Atrophy 5 C1853139. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy